A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer

Since the prognosis of advanced biliary tract cancer (aBTC) still remains very poor, new therapeutic approaches, including immunotherapies, need to be developed. In the current study, we conducted an open‐label randomized phase II study to test whether low dose cyclophosphamide (CPA) could improve a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirahama, Takahisa, Muroya, Daisuke, Matsueda, Satoko, Yamada, Akira, Shichijo, Shigeki, Naito, Masayasu, Yamashita, Takuto, Sakamoto, Shinjiro, Okuda, Koji, Itoh, Kyogo, Sasada, Tetsuro, Yutani, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448649/
https://www.ncbi.nlm.nih.gov/pubmed/28188670
http://dx.doi.org/10.1111/cas.13193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448649/
https://www.ncbi.nlm.nih.gov/pubmed/28188670
http://dx.doi.org/10.1111/cas.13193

Ejemplares similares